PROGNOSTIC SIGNIFICANCE OF P16 IN LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK TREATED WITH CONCURRENT CISPLATIN AND RADIOTHERAPY

Background. Human papillomavirus (HPV)related squamous cell cancer of the head and neck (SCCHN) has emerged as a distinct clinical entity. The expression of p16 protein can be used as a surrogate for HPV status. Methods. p16 immunohistochemistry (IHC) was assessed in archival paraffin-embedded material for 55 patients with locally advanced SCCHN treated with a uniform regimen of cisplatin and radiation. HPV status was assessed by colorimetric in situ hybridization (CISH) and polymerase chain reaction (PCR). Results. Compared with p16- and HPV-negative patients, the p1.6- and HPV-positive patients had improved overall survival, disease-free survival, and locoregional recurrence rates. Conclusions. p16 IHC may serve as a useful surrogate and prognostic marker for patients with HPV-related SCCHN treated with cisplatin and radiation. (C) 2010 Wiley Periodicals, Inc. Head Neck 33: 251-256, 2011